We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Lifemel Honey to Reduce Leucopenia During Chemotherapy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2005 by Rambam Health Care Campus.
Recruitment status was:  Not yet recruiting
ClinicalTrials.gov Identifier:
First Posted: October 21, 2005
Last Update Posted: December 7, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Zuf Globus Laboratories Ltd.
Information provided by:
Rambam Health Care Campus
This study will include 60 patients with early breast cancer referred to receive adjuvant chemotherapy with AC ( adriamycin- cyclophosphamide) or CAF ( adriamycin- cyclophosphamide- 5- fluorouracil ) combinations. These patients will receive every day one spoon of Lifemel honey or regular honey ( double blind)- during the adjuvant chemotherapy .Every week a WBC count will be performed in order to record the influence of Lifemel on myelotoxicity.

Condition Intervention Phase
Breast Cancer Behavioral: Lifemel honey intake every day Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia

Resource links provided by NLM:

Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:
  • Prevention of myelotoxicity-every week during chemotherapy.

Estimated Enrollment: 60
Study Start Date: November 2005

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • breast cancer patient treated with adjuvant chemotherapy
  • PS = 2 or less

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00243165

Contact: Georgeta Fried, MD 972-4-8543018 g_fried@rambam.health.gov.il

Sponsors and Collaborators
Rambam Health Care Campus
Zuf Globus Laboratories Ltd.
Principal Investigator: Georgeta Fried, MD Rambam Health Care Campus
  More Information

ClinicalTrials.gov Identifier: NCT00243165     History of Changes
Other Study ID Numbers: LifemelCTIL
First Submitted: October 20, 2005
First Posted: October 21, 2005
Last Update Posted: December 7, 2009
Last Verified: October 2005

Keywords provided by Rambam Health Care Campus:
breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Leukocyte Disorders
Hematologic Diseases